Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation
- PMID: 20157216
Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation
Abstract
Objectives: To detect and enumerate circulating prostatic tumor cells (CTC) in the peripheral blood of patients with prostate cancer (PC) and study the relationship between CTCs and clinical-pathological parameters.
Methods: Prospective three-arm study: 26 patients (p) with localised PC (LPC); 24 P with metastatic PC (MPC) and 30 healthy volunteer controls. A single 7.5 ml sample of peripheral blood was retrieved; CTCs were isolated using an immunomagnetic method based on the CellSearch system (Veridex). CTCs were identified as nucleated cells negative for CD45 (leukocytes) and positive for cytokeratins. (8, 18 y 19) The relationship between CTC numbers and PSA levels, Gleason score and TNM classification was studied.
Results: Only 10% of the healthy controls had 1 CTC/7.5 mL, none of the patients with localised PC had more than 3 CTCs (88% < or = 2 CTCs), and patients with MPC had significantly higher CTC levels [m: 29 (1-178)] compared with the other two groups (P: 0.000). A positive correlation was demonstrated between the CTC count and PSA levels, tumor size, and presence or absence of enlarged lymph nodes. Gleason score was the only parameter that did not show any correlation with CTC levels, and although the number of CTCs was higher in patients with visceral metastases [m: 297 (0-416)] compared with bone metastases patients [m: 68 (9.5-168)] , these differences were not significant.
Conclusions: Immunomagnetic analysis permits CTCs to be enumerated in peripheral blood and could be a possible way to correctly stage and make a reasonable prognosis of metastatic disease.
Similar articles
-
Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.Urology. 2012 Dec;80(6):1328-32. doi: 10.1016/j.urology.2012.09.001. Epub 2012 Oct 10. Urology. 2012. PMID: 23063057
-
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15. J Urol. 2008. PMID: 18707699
-
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923. J Clin Oncol. 2008. PMID: 18591556
-
Image cytometry analysis of circulating tumor cells.Methods Cell Biol. 2011;102:261-90. doi: 10.1016/B978-0-12-374912-3.00010-9. Methods Cell Biol. 2011. PMID: 21704842 Review.
-
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.J Urol. 1997 Aug;158(2):326-37. J Urol. 1997. PMID: 9224297 Review.
Cited by
-
Clinical Applications of Liquid Biopsy in Gastric Cancer.Front Med (Lausanne). 2021 Sep 28;8:749250. doi: 10.3389/fmed.2021.749250. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34651002 Free PMC article. Review.
-
Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications.World J Clin Oncol. 2021 Dec 24;12(12):1169-1181. doi: 10.5306/wjco.v12.i12.1169. World J Clin Oncol. 2021. PMID: 35070736 Free PMC article. Review.
-
Unlocking the Potential of Liquid Biopsy: A Paradigm Shift in Endometrial Cancer Care.Diagnostics (Basel). 2025 Jul 30;15(15):1916. doi: 10.3390/diagnostics15151916. Diagnostics (Basel). 2025. PMID: 40804879 Free PMC article. Review.
-
The Role of Liquid Biopsy in the Diagnosis and Prognosis of WHO Grade 4 Astrocytoma.Cureus. 2023 Jun 30;15(6):e41221. doi: 10.7759/cureus.41221. eCollection 2023 Jun. Cureus. 2023. PMID: 37525780 Free PMC article. Review.
-
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.Front Immunol. 2023 May 22;14:1171649. doi: 10.3389/fimmu.2023.1171649. eCollection 2023. Front Immunol. 2023. PMID: 37283751 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous